Wall Street Zen Upgrades Penumbra (NYSE:PEN) to Buy

Penumbra (NYSE:PEN) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Saturday.

Other equities research analysts have also recently issued reports about the stock. Citigroup raised shares of Penumbra from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $285.00 to $350.00 in a research report on Thursday, December 11th. Evercore ISI reaffirmed an “outperform” rating and set a $286.00 target price on shares of Penumbra in a research report on Thursday, November 6th. Canaccord Genuity Group lifted their price objective on Penumbra from $355.00 to $359.00 and gave the company a “buy” rating in a report on Wednesday. Robert W. Baird set a $345.00 target price on shares of Penumbra in a report on Tuesday. Finally, Wells Fargo & Company initiated coverage on shares of Penumbra in a research note on Tuesday, November 18th. They set an “underweight” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Penumbra currently has an average rating of “Moderate Buy” and a consensus target price of $333.47.

Penumbra Trading Up 0.2%

PEN opened at $315.98 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 6.73. The stock’s 50 day moving average price is $274.47 and its 200-day moving average price is $260.85. Penumbra has a one year low of $221.26 and a one year high of $320.00. The stock has a market cap of $12.37 billion, a price-to-earnings ratio of 75.59, a P/E/G ratio of 2.60 and a beta of 0.66.

Penumbra (NYSE:PEN) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.90 by $0.07. Penumbra had a return on equity of 11.35% and a net margin of 12.30%.The company had revenue of $354.69 million for the quarter, compared to the consensus estimate of $340.77 million. During the same quarter in the prior year, the company posted $0.85 EPS. Penumbra’s quarterly revenue was up 17.8% on a year-over-year basis. On average, equities analysts forecast that Penumbra will post 3.67 EPS for the current year.

Insider Buying and Selling at Penumbra

In other Penumbra news, Director Harpreet Grewal sold 100 shares of the firm’s stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $292.98, for a total value of $29,298.00. Following the completion of the sale, the director owned 8,416 shares of the company’s stock, valued at approximately $2,465,719.68. This trade represents a 1.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Johanna Roberts sold 300 shares of the stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $300.13, for a total transaction of $90,039.00. Following the completion of the transaction, the executive vice president directly owned 63,836 shares of the company’s stock, valued at $19,159,098.68. The trade was a 0.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 34,744 shares of company stock worth $10,387,474. 4.20% of the stock is owned by insiders.

Institutional Trading of Penumbra

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PEN. Invesco Ltd. grew its stake in Penumbra by 1,139.3% during the 2nd quarter. Invesco Ltd. now owns 633,485 shares of the company’s stock valued at $162,571,000 after purchasing an additional 582,369 shares during the last quarter. Norges Bank acquired a new position in Penumbra in the 2nd quarter worth approximately $114,014,000. Holocene Advisors LP purchased a new position in Penumbra during the 3rd quarter worth approximately $78,585,000. Qube Research & Technologies Ltd acquired a new stake in Penumbra during the 2nd quarter valued at approximately $53,818,000. Finally, Man Group plc increased its stake in shares of Penumbra by 1,862.2% in the second quarter. Man Group plc now owns 206,461 shares of the company’s stock worth $52,984,000 after acquiring an additional 195,939 shares during the period. Institutional investors and hedge funds own 88.88% of the company’s stock.

Penumbra News Roundup

Here are the key news stories impacting Penumbra this week:

• Positive Sentiment: JPMorgan upgraded PEN from Neutral to Overweight and bumped its target to $370 (from $275), signaling stronger conviction in Penumbra’s growth trajectory and implying meaningful upside vs. the current share level. JP Morgan Upgrades Penumbra (PEN)
• Positive Sentiment: Truist raised its price target to $370 from $312 and reiterated a Buy, reinforcing the bullish view and matching JPMorgan’s $370 target that implies roughly mid‑teens upside from current levels. Penumbra upgraded to overweight from neutral at JPMorgan
• Positive Sentiment: Additional price-target lifts from RBC (to $355 from $325) and Canaccord (to $359 from $355) add to the consensus upward drift in sell‑side expectations. These moves tighten the buy-side narrative around recurring CAVT adoption and international growth. Penumbra price target raised to $359 from $355 at Canaccord Penumbra price target raised to $355 from $325 at RBC Capital
• Positive Sentiment: Needham reiterated a Buy rating, supporting the positive analyst tone and reducing near‑term downside risk from the sell‑side. Needham maintains Penumbra (PEN) buy recommendation
• Positive Sentiment: Clinical/outcomes coverage: a published evaluation of Penumbra’s CAVT in intermediate‑risk pulmonary embolism (PE) patients highlights outcomes and resource‑utilization benefits—supportive evidence for broader clinical adoption and reimbursement discussions. Penumbra’s CAVT Evaluated for Outcomes and Resource Utilization in Intermediate-Risk PE Patients
• Neutral Sentiment: Media/awareness: Bloomberg’s healthcare segment highlighted Penumbra’s efforts to expand CAVT awareness—positive for long‑term market penetration but more of a brand/voice play than an immediate revenue driver. Vanguards of Health Care: Penumbra Expands CAVT Awareness

About Penumbra

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.